- June 28, 2020
- Posted by: OptimizeIAS Team
- Category: DPN Topics
Subject: Science and tech
- As part of the RECOVERY trial, a range of potential treatments is being tested in patients being admitted to the UK National Health Service (NHS) hospitals that are positive for COVID-19.
- Sponsored by Oxford University in England, the trial is assessing the effectiveness of different potential COVID-19 treatments on their ability to reduce all-cause (overall) mortality within 28 days.
- RECOVERY Trial is testing a handful of drugs in consenting patients:
- Lopinavir-Ritonavir (commonly used to treat HIV)
- Low-dose Dexamethasone (a corticosteroid medicine used to treat inflammation)
- Hydroxychloroquine (an anti-malarial drug used to prevent and treat malaria in areas where malaria is sensitive to chloroquine)
- Azithromycin (a commonly-used antibiotic)
- Tocilizumab (an anti-inflammatory treatment given by injection)
- Convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus).